Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

NCT04391283 ·Status: UNKNOWN

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857 ·Status: RECRUITING

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ·Status: COMPLETED ·Phase: PHASE2

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683 ·Status: COMPLETED

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02151981 ·Status: COMPLETED ·Phase: PHASE3

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

NCT05219162 ·Status: COMPLETED ·Phase: PHASE4

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

NCT04105153 ·Status: COMPLETED

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

NCT02959749 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

NCT03543683 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936 ·Status: SUSPENDED